Alphamab Oncology Buys Back 115,000 Shares, Lifting Treasury Stock to 6.22 Million

Bulletin Express09-02 23:22

Alphamab Oncology (Alphamab) disclosed that it repurchased 115,000 ordinary shares on 2 September 2026 through on-market transactions on the Hong Kong Stock Exchange. The shares were acquired at prices ranging from HKD 8.43 to HKD 8.62, with a volume-weighted average purchase price of HKD 8.57. The aggregate consideration amounted to HKD 0.99 million.

Following the transaction, Alphamab’s issued share capital (excluding treasury shares) fell to 968.17 million shares, a marginal reduction of 0.0119% from the previous day. Treasury shares rose to 6.22 million, while the total issued share count remained unchanged at 974.38 million.

The buyback was executed under the authority granted by shareholders on 12 June 2026, which permits the company to repurchase up to 96.85 million shares. Including the latest purchase, Alphamab has repurchased 340,000 shares under this mandate, equivalent to 0.0351% of the company’s outstanding shares as at the mandate date.

A moratorium prohibits Alphamab from issuing new shares or disposing of treasury shares until 2 October 2026, in accordance with Hong Kong Stock Exchange rules.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130240076?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-02 23:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130240076","market":"hk","top_or_hot":-1,"title":"Alphamab Oncology Buys Back 115,000 Shares, Lifting Treasury Stock to 6.22 Million","media":"Bulletin Express","content":"<p>Alphamab Oncology (Alphamab) disclosed that it repurchased 115,000 ordinary shares on 2 September 2026 through on-market transactions on the Hong Kong Stock Exchange. The shares were acquired at prices ranging from HKD 8.43 to HKD 8.62, with a volume-weighted average purchase price of HKD 8.57. The aggregate consideration amounted to HKD 0.99 million.</p>\n<p>Following the transaction, Alphamab’s issued share capital (excluding treasury shares) fell to 968.17 million shares, a marginal reduction of 0.0119% from the previous day. Treasury shares rose to 6.22 million, while the total issued share count remained unchanged at 974.38 million.</p>\n<p>The buyback was executed under the authority granted by shareholders on 12 June 2026, which permits the company to repurchase up to 96.85 million shares. Including the latest purchase, Alphamab has repurchased 340,000 shares under this mandate, equivalent to 0.0351% of the company’s outstanding shares as at the mandate date.</p>\n<p>A moratorium prohibits Alphamab from issuing new shares or disposing of treasury shares until 2 October 2026, in accordance with Hong Kong Stock Exchange rules.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alphamab Oncology Buys Back 115,000 Shares, Lifting Treasury Stock to 6.22 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlphamab Oncology Buys Back 115,000 Shares, Lifting Treasury Stock to 6.22 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-02 23:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Alphamab Oncology (Alphamab) disclosed that it repurchased 115,000 ordinary shares on 2 September 2026 through on-market transactions on the Hong Kong Stock Exchange. The shares were acquired at prices ranging from HKD 8.43 to HKD 8.62, with a volume-weighted average purchase price of HKD 8.57. The aggregate consideration amounted to HKD 0.99 million.</p>\n<p>Following the transaction, Alphamab’s issued share capital (excluding treasury shares) fell to 968.17 million shares, a marginal reduction of 0.0119% from the previous day. Treasury shares rose to 6.22 million, while the total issued share count remained unchanged at 974.38 million.</p>\n<p>The buyback was executed under the authority granted by shareholders on 12 June 2026, which permits the company to repurchase up to 96.85 million shares. Including the latest purchase, Alphamab has repurchased 340,000 shares under this mandate, equivalent to 0.0351% of the company’s outstanding shares as at the mandate date.</p>\n<p>A moratorium prohibits Alphamab from issuing new shares or disposing of treasury shares until 2 October 2026, in accordance with Hong Kong Stock Exchange rules.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09966","symbol_name":"康宁杰瑞制药-B","start_time":0,"source_url":"","article_id":"1130240076","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130240076","pubTimestamp":1788362554,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Alphamab Oncology (Alphamab) disclosed that it repurchased 115,000 ordinary shares on 2 September 2026 through on-market transactions on the Hong Kong Stock Exchange. The shares were acquired at...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09966":"康宁杰瑞制药-B"},"translate_title":"康宁杰瑞肿瘤回购11.5万股股票，库存股增至622万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09966":1},"content_text":"Alphamab Oncology (Alphamab) disclosed that it repurchased 115,000 ordinary shares on 2 September 2026 through on-market transactions on the Hong Kong Stock Exchange. The shares were acquired at prices ranging from HKD 8.43 to HKD 8.62, with a volume-weighted average purchase price of HKD 8.57. The aggregate consideration amounted to HKD 0.99 million.\nFollowing the transaction, Alphamab’s issued share capital (excluding treasury shares) fell to 968.17 million shares, a marginal reduction of 0.0119% from the previous day. Treasury shares rose to 6.22 million, while the total issued share count remained unchanged at 974.38 million.\nThe buyback was executed under the authority granted by shareholders on 12 June 2026, which permits the company to repurchase up to 96.85 million shares. Including the latest purchase, Alphamab has repurchased 340,000 shares under this mandate, equivalent to 0.0351% of the company’s outstanding shares as at the mandate date.\nA moratorium prohibits Alphamab from issuing new shares or disposing of treasury shares until 2 October 2026, in accordance with Hong Kong Stock Exchange rules.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130240076","isCrawlerRequest":true}